Table 1 Summary of Patient, Tumor, and Treatment Characteristics.
From: Genomic copy number variation correlates with survival outcomes in WHO grade IV glioma
Variable | Level | N = 56 (%) |
|---|---|---|
Patient Characteristics | ||
Age (years) | Median (range) | 60.4 (26.1-86.3) |
Gender | Male | 34 (60.7%) |
Female | 22 (39.3%) | |
KPS | ≤ 70 | 23 (42.6%) |
> 70 | 31 (57.4%) | |
Surgery | Biopsy | 6 (10.9%) |
GTR | 14 (25.5%) | |
STR | 35 (63.6%) | |
Radiotherapy | ≥ 60 Gy | 44 (86.2%) |
< 60 Gy | 7 (13.7%) | |
Concurrent temozolomide | Yes | 44 (78.5%) |
No | 5 (8.9%) | |
Unknown | 7 (12.5%) | |
Adjuvant chemotherapy | Yes | 38 (67.8%) |
No | 8 (14.3%) | |
Unknown | 10 (17.8%) | |
Tumor Characteristics | ||
MGMT methylation | Unmethylated | 31 (55.4%) |
Methylated/partially methylated | 25 (44.6%) | |
IDH1 mutation | Negative | 50 (89.3%) |
Positive | 6 (10.7%) | |
1p19q co-deletion | No | 51 (91.1%) |
Yes | 4 (7.1%) | |
Unknown | 1 (1.8%) | |
ASCAT ploidy (numeric) | Median (SD) | 2.05 (0.55) |
Range | (1.64-4.05) | |
ASCAT log R segment counts (numeric) | Median (SD) | 371 (92.23) |
Range | (233-646) | |
ASCAT BAF segment counts (numeric) | Median (SD) | 266 (96.93) |
Range | (156-572) | |
ASCAT ACF (numeric) | Median (SD) | 0.78 (0.55) |
Range | (0.29-1) | |
